111 results on '"Loomba R"'
Search Results
2. EPH9 Non-Alcoholic Fatty Liver Disease Awareness in the United States: National Health and Nutrition Examination Survey Data 1999-2020
3. HTA2 Cost-Effectiveness of a Clinical Care Pathway for the Screening of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
4. COMPARISON OF THE EFFECTS OF SEMAGLUTIDE ON LIVER HISTOLOGY IN PATIENTS WITH NON-ALCOHOLICS STEATOHEPATITIS CIRRHOSIS BETWEEN MACHINE LEARNING MODEL ASSESSMENT AND PATHOLOGIST EVALUATION
5. COMPARISON OF THE EFFECTS OF SEMAGLUTIDE ON LIVER HISTOLOGY IN PATIENTS WITH NON-ALCOHOLICS STEATOHEPATITIS CIRRHOSIS BETWEEN MACHINE LEARNING MODEL ASSESSMENT AND PATHOLOGIST EVALUATION
6. Editorial: first‐degree relatives of Mexican Americans with HCC are at increased risk of significant fibrosis—authors' reply
7. A219 AMINOTRANSFERASE IMPROVEMENTS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ARE ASSOCIATED WITH FIBROSIS REGRESSION IN THE REGENERATE STUDY
8. AF.81 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL
9. PC.01.9 EVALUATION OF OBETICHOLIC ACID EFFICACY IN PATIENTS WITH NASH WHO WERE MONITORED USING NONINVASIVE TESTS: A POST HOC ANALYSIS OF THE REGENERATE TRIAL
10. P0323 / #365: EFFECTS OF INHALED NITRIC OXIDE ON HEMODYNAMICS AND GAS EXCHANGE IN CHILDREN AFTER HAVING UNDERGONE CARDIAC SURGERY UTILIZING CARDIOPULMONARY BYPASS
11. Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: Results of a post hoc analysis from the interim analysis of the REGENERATE study
12. O032 / #343: BETA-BLOCKADE AFTER COMPLETE REPAIR OF TETRALOGY OF FALLOT DOES NOT DECREASE COST OF ADMISSION OR INPATIENT MORTALITY
13. A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL
14. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease
15. Obeticholic Acid Efficacy in Patients With NASH Monitored Using Noninvasive Tests: Post Hoc Analysis of REGENERATE Trial
16. T06.01.12 OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY
17. OC.05.5 OBETICHOLIC ACID TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: A SECONDARY ANALYSIS OF THE REGENERATE STUDY ACROSS FIBROSIS STAGES
18. Obeticholic acid treatment in patients with non-alcoholic steatohepatitis: a secondary analysis of the REGENERATE study across fibrosis stages
19. Obeticholic acid (OCA) improves experimental non-invasive markers of NASH and advanced fibrosis: results of a secondary analysis from the month-18 interim analysis of the REGENERATE study
20. PDB93 NAFLD SIMULATOR: A WEB-BASED SIMULATION TOOL TO PREDICT LONG-TERM OUTCOMES OF NON-ALCOHOLIC FATTY LIVER DISEASE
21. Obeticholic Acid Treatment in Patients with Non-Alcoholic Steatohepatitis: A Secondary Analysis of the Regenerate Study Across Fibrosis Stages
22. Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis
23. Blood pressure levels and hypertension prevalence in a high selenium environment: results from a cross-sectional study
24. P6194Factors associated with the need for, and the impact of, extracorporeal membrane oxygenation in children with congenital heart disease during admissions for cardiac surgery
25. P6193Trends and outcomes of hospitalization for pediatric cardiac arrest and their association with underlying heart disease
26. P5486Vestibular atrial septal defects: a novel atrial septal defect
27. Editorial: role of leucine-metformin-sildenafil combination in the treatment of nonalcoholic fatty liver disease (NAFLD)
28. Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study
29. Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH
30. Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model
31. Whole exome sequencing identifies rare nonsense mutations enriched among patients with advanced fibrosis due to nonalcoholic steatohepatitis
32. Stage-specific benefits of treatment associated fibrosis regression in patients with NASH: a Markov modeling approach
33. Serum bile acids alteration is associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD
34. Validation of a quantitative imaging assessment biomarker metric for MRI-estimated proton density fat fraction in a large multi-center clinical trial
35. The association of circulating microRNAs (miRs) with liver fibrosis stage and the impact of selonsertib treatment in patients with NASH
36. Health care costs are double for non-alcoholic fatty liver disease non-alcoholic steatohepatitis patients with compensated cirrhosis who progress to end-stage liver disease
37. Novel characterization of the gut microbiome in patients with NASH and longitudinal changes associated with histological improvement
38. Characterization of changes in lipoprotein profiles of patients with nonalcoholic steatohepatitis treated with the acetyl-CoA carboxylase inhibitor GS-0976
39. Responsiveness of controlled attenuation parameter (CAP) and its correlation with magnetic resonance imaging-proton density fat fraction (MRI-PDFF) in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis (NASH)
40. Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD
41. Magnetic Resonance Elastography versus Transient Elastography in detection of fibrosis in nonalcoholic fatty liver disease: A systematic review and meta-analysis of individual participant date
42. Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH)
43. FIBROSpect ® NASH serum test identifies advanced liver fibrosis in patients with nonalcoholic steatohepatitis: Results of a validation study
44. Even modest alcohol use is associated with greater steatosis on magnetic resonance imaging in patients with NAFLD – a pilot study
45. A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
46. Editorial: non‐alcoholic fatty liver disease―a pandemic in need of novel treatments and endpoints
47. Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor NAFLD - authors’ reply
48. P.09.14: Magnitude of Liver Stiffness Regression after Achieving Sustained Virologic Response in Patients with Chronic Hepatitis C: A Meta-Analysis
49. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging
50. Letter: comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven NAFLD - author's reply
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.